Dimensional Fund Advisors LP increased its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 3.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 129,320 shares of the medical instruments supplier’s stock after acquiring an additional 4,634 shares during the quarter. Dimensional Fund Advisors LP owned approximately 3.44% of Mesa Laboratories worth $18,532,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in MLAB. Strs Ohio lifted its stake in Mesa Laboratories by 5.6% in the second quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock worth $272,000 after acquiring an additional 100 shares during the period. BT Investment Management Ltd bought a new position in Mesa Laboratories in the second quarter worth about $277,000. Spark Investment Management LLC bought a new position in Mesa Laboratories in the second quarter worth about $300,000. Alliancebernstein L.P. raised its holdings in Mesa Laboratories by 52.9% in the second quarter. Alliancebernstein L.P. now owns 2,600 shares of the medical instruments supplier’s stock worth $373,000 after purchasing an additional 900 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Mesa Laboratories by 2.3% in the second quarter. PNC Financial Services Group Inc. now owns 3,117 shares of the medical instruments supplier’s stock worth $446,000 after purchasing an additional 71 shares in the last quarter. 68.50% of the stock is owned by institutional investors.

Mesa Laboratories, Inc. (NASDAQ MLAB) opened at $125.84 on Friday. Mesa Laboratories, Inc. has a fifty-two week low of $109.14 and a fifty-two week high of $169.80. The company has a current ratio of 2.86, a quick ratio of 1.37 and a debt-to-equity ratio of 0.48. The stock has a market cap of $480.10, a PE ratio of 33.60 and a beta of 0.49.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings data on Monday, November 6th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.64 by ($0.04). Mesa Laboratories had a net margin of 11.48% and a return on equity of 14.77%. The company had revenue of $22.95 million for the quarter, compared to analyst estimates of $25.50 million. sell-side analysts forecast that Mesa Laboratories, Inc. will post 2.47 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Thursday, November 30th will be issued a dividend of $0.16 per share. The ex-dividend date is Wednesday, November 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.51%. Mesa Laboratories’s dividend payout ratio (DPR) is currently 23.10%.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/10/dimensional-fund-advisors-lp-grows-position-in-mesa-laboratories-inc-mlab.html.

A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Mesa Laboratories from a “buy” rating to a “strong sell” rating in a report on Friday. TheStreet upgraded shares of Mesa Laboratories from a “c+” rating to a “b” rating in a report on Monday. Finally, BidaskClub downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a report on Monday, July 31st.

In related news, Director H Stuart Campbell sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $130.16, for a total value of $130,160.00. Following the sale, the director now owns 42,366 shares in the company, valued at $5,514,358.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 3,002 shares of company stock worth $391,268. Corporate insiders own 15.70% of the company’s stock.

Mesa Laboratories Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.